 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
20188 News |  |
| «12...160161162163164165166167168169170...208209» |
- The Use of Combination Biologic or Small Molecule Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study () - Dec 11, 2019 - Abstract #AIBD2019AIBD_29;
Patients had failed therapy with an average of 2 previous biologic medications. There were significantly more patients in clinical and endoscopic remission at follow up, 50% vs 14%, P = 0.002, delta 33%; 95% CI 0.13–0.53, and 34% vs 6%, P = 0.004, delta 28%; 95% CI 0.09–0.47 respectively.
- Humira (adalimumab) / Eisai, AbbVie
Microscopic Colitis With Quiescent Crohn’s Disease: A Case Report () - Dec 11, 2019 - Abstract #AIBD2019AIBD_17;
We report a case of Crohn’s disease whose clinical course was complicated by collagenous colitis while on adalimumab...She was placed back on budesonide 9 mg daily which resolved her symptoms of diarrhea...The association between collagenous colitis and IBD is still unclear. In patients with Ulcerative Colitis or Crohn’s disease, the onset of new symptoms of non-bloody diarrhea with no signs of IBD relapse on endoscopy, mucosal biopsies should be obtained to rule out MC.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Successful Use of Combination Biologic Therapy in Medically Refractory Pediatric Crohn's Disease and Sacroiliitis () - Dec 11, 2019 - Abstract #AIBD2019AIBD_13;
He had sub-optimal clinical improvement on anti-tumor necrosis factor (TNF) therapy that included infliximab for 1 year, followed by adalimumab for 1.5 years...At the time of presentation to our center he was steroid dependent on prednisone 5 mg daily for 6 months while still on vedolizumab and azathioprine...He was treated with Budesonide MMX and mesalamine enemas with no improvement...Adalimumab and oral methotrexate were given in addition to vedolizumab...When used judiciously in patients with medically refractory disease it can be safe and effective. A paucity of literature exists regarding the use of combination biologicals especially in children.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Case Study of a Patient With Crohn's Disease and Surgical Wound Dehiscence () - Dec 11, 2019 - Abstract #AIBD2019AIBD_11;
Refractory to Adalimumab, using Infliximab 10mg/kg every 8 weeks and Azathioprine 50 mg/day. In this context, it was clear that the nurses' knowledge about the disease, the correct management of postoperative complications enabled the more agile and effective progress of wound treatment, favoring better quality of life for the patient and allowing reflection on the subject exposed.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Correlation Between Histological Activity and Use of Anti-TNF in Patients With Inflammatory Bowel Disease in a Mexican Tertiary Hospital Centre () - Dec 11, 2019 - Abstract #AIBD2019AIBD_5;
The most used anti-TNF in patients with Crohn's disease was Adalimumab and Certolizumab in an equitable percentage with 38.9%. On the other hand, infliximab was the least used, with 22.2%.
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (clinicaltrials.gov) - Dec 11, 2019
P=N/A, N=483, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
On the other hand, infliximab was the least used, with 22.2%. Active, not recruiting --> Completed
- | ABBV-3373 / AbbVie
Phase classification, Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Dec 11, 2019
P2, N=45, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Phase classification: P1 --> P2 | Trial completion date: Aug 2020 --> Jun 2021 | Trial primary completion date: Aug 2020 --> Dec 2020
- | Humira (adalimumab) / AbbVie
New P4 trial: ADDORA: Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring (clinicaltrials.gov) - Dec 10, 2019
P4, N=267, Recruiting, Sponsor: Reade Rheumatology Research Institute
- | Humira (adalimumab) / Eisai, AbbVie
Es importante bajar el precio de Humira, no creen? (Twitter) - Dec 9, 2019
- | Humira (adalimumab) / Eisai, AbbVie
@abbvie that commercial for Humira is really creepy. And offensive. #humira (Twitter) - Dec 9, 2019
- Orencia (abatacept) / BMS
Enrollment open: AMiRA: Effects of Abatacept on Myocarditis in Rheumatoid Arthritis (clinicaltrials.gov) - Dec 9, 2019
P4, N=20, Recruiting, Sponsor: Columbia University
Phase classification: P1 --> P2 | Trial completion date: Aug 2020 --> Jun 2021 | Trial primary completion date: Aug 2020 --> Dec 2020 Not yet recruiting --> Recruiting
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Humira (adalimumab) / AbbVie
Trial completion date, Trial primary completion date: DIPIT: Diabetes Islet Preservation Immune Treatment (clinicaltrials.gov) - Dec 9, 2019
P1/2, N=42, Not yet recruiting, Sponsor: Camillo Ricordi and Jay Skyler
Not yet recruiting --> Recruiting Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Jun 2023
- | Humira (adalimumab) / AbbVie
Enrollment open, Monotherapy: CoCroS: Control Crohn Safe Trial (clinicaltrials.gov) - Dec 9, 2019
P4, N=158, Enrolling by invitation, Sponsor: Maastricht University Medical Center
Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Jun 2023 Not yet recruiting --> Enrolling by invitation
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Aspects concerning patient adherence to anti-TNFα therapy in psoriasis: A decade of clinical experience. (Pubmed Central) - Dec 8, 2019
The main adverse effects that occurred during anti-TNFα therapy were: local reaction to the drug, mild infectious events, allergic reactions, cardiotoxicity, alopecia areata, pancreatitis, eosinophilia, thrombocytopenia. Anti-TNF therapy was discontinued in one case of endocarditis, one case with tuberculous laryngitis and another one with polydiscitis (Adalimumab), a case of colon cancer and one of pregnancy (Etanercept) and one paradoxical reaction (Infliximab).
- || Clinical, Journal: Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics. (Pubmed Central) - Dec 8, 2019
P=N/A
Age, PGA 4, 5, history of infection, and diabetes were associated with an increased risk for SI, irrespective of biologic exposure. NCT00508547; Registered July 30, 2007.
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira SC (adalimumab/hyaluronidase) / AbbVie, Halozyme Therapeutics, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Successful treatment of pediatric Tolosa-Hunt syndrome with adalimumab. (Pubmed Central) - Dec 8, 2019
NCT00508547; Registered July 30, 2007. Adalimumab, a subcutaneous TNFi, appears to be an effective treatment for corticosteroid-dependent THS.
- || Humira (adalimumab) / Eisai, AbbVie
Anecdotally, I’ve seen it be at least as effective as Humira. My last colonoscopy looked great and flares are limited to potential CIIPO which is being treated with other meds. Idk! Seems promising! (Twitter) - Dec 7, 2019
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: The cost of the biosimulars will only come down if we are willing to switch to the cheapest. As some one who switched 112 adalimumab patients a year ago and is now being told that we may switch to a cheaper rival, I have concerns about disruption to patients, when will it end? (Twitter) - Dec 7, 2019
- || Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Therapeutic strategy for Rheumatoid Arthritis Patients who have achieved Remission. (Pubmed Central) - Dec 6, 2019
The risk of structural damage progression was minimal or null. Reintroduction of DMARD at the previous dose was associated with remission being achieved in the majority of patients who flared.Tapering strategies that adhere to the Tight Control and Treat-to-Target principles appear to be suitable options for RA patients who have achieved sustained remission or low disease activity.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Journal: ANNALS EXPRESS: Therapeutic drug monitoring of TNF inhibitors in the management of chronic inflammatory diseases. (Pubmed Central) - Dec 6, 2019
Although prospective controlled trials yield little conclusive evidence of its benefits, there is growing acceptance of its value in clinical practice. Keywords Drug monitoring, TNF-alpha inhibitor, Antidrug antibody, Chronic inflammatory diseases, Infliximab, Adalimumab, Etanercept.
- ||| bimekizumab (UCB4940) / UCB, Humira (adalimumab) / Eisai, AbbVie
Head-to-Head: UCB buffs up in blockbuster psoriasis race as bimekizumab beats Humira in head-to-head https://t.co/t2o37DaSeF (Twitter) - Dec 6, 2019
- | methotrexate / Generic Mfg., Humira (adalimumab) / Eisai, AbbVie
Journal: Methotrexate Reduces the Clearance of Adalimumab by Increasing the Concentration of Neonatal Fc Receptor in Tissues. (Pubmed Central) - Dec 6, 2019
Keywords Drug monitoring, TNF-alpha inhibitor, Antidrug antibody, Chronic inflammatory diseases, Infliximab, Adalimumab, Etanercept. FcRn may play a vital role in the interaction between adalimumab and MTX.
- |||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Commentary to our TDM paper by Dr Wael El-Matary, Therapeutic Drug Monitoring of Adalimumab in Patients with Inflammatory Bowel Disease @sang_hyoung @EdwardLoftus2 #CC360 https://t.co/wambaufjRM (Twitter) - Dec 5, 2019
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Stricture Definition and Treatment (STRIDENT) Drug Therapy Study (clinicaltrials.gov) - Dec 5, 2019
P4, N=78, Active, not recruiting, Sponsor: St Vincent's Hospital Melbourne
FcRn may play a vital role in the interaction between adalimumab and MTX. Recruiting --> Active, not recruiting
- |||||| Jyseleca (filgotinib) / Galapagos, Gilead
Enrollment open: PENGUIN 1: Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy (clinicaltrials.gov) - Dec 5, 2019
P3, N=1001, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| etrolizumab (RG7413) / Roche
Enrollment closed: HIBISCUS II: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Dec 4, 2019
P3, N=350, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service (Plenary Hall) - Dec 3, 2019 - Abstract #ECCOIBD2020ECCO_IBD_54;
Conclusion We report lower positivity thresholds for the IDKmonitor® total anti-TNF antibody ELISA assays than the manufacturer, in particular, for adalimumab. Transient antibody formation is uncommon: most patients develop persistent anti-drug antibodies that lead to drug clearance.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Higher vs. standard adalimumab maintenance regimens in patients with moderately to severely active ulcerative colitis: Results from the SERENE-UC maintenance study (Plenary Hall) - Dec 3, 2019 - Abstract #ECCOIBD2020ECCO_IBD_6;
P3
Higher maintenance treatment with 40 EW was generally safe and well tolerated with a similar safety profile to 40 EOW. No new long-term safety concerns were observed.
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P4 trial: A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab (clinicaltrials.gov) - Dec 3, 2019
P4, N=238, Not yet recruiting, Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- | Humira (adalimumab) / Eisai, AbbVie
Retrospective data, Journal: Detailed ANA dynamics under adalimumab therapy show no significant correlation to PASI response and MTX co-treatment: a retrospective study of 98 psoriasis patients. (Pubmed Central) - Dec 2, 2019
The clinical implications of ANA induction in psoriasis patients are, however, still unclear. In particular, data regarding its association to treatment response is controversial and no data is available on its detailed dynamics.
- ||| Humira (adalimumab) / Eisai, AbbVie
I took Humira for Crohn’s and it gave me an almost-ICU stay for a respiratory infection and recurrent skin issues I can’t get rid of despite seeing multiple dermatologists. I’m not impressed at either the drug or the unwarranted increases in cost, which somebody is paying. (Twitter) - Dec 2, 2019
- || Clinical, Review, Journal: British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. (Pubmed Central) - Dec 1, 2019
Comprehensive up-to-date guidance is provided regarding indications for, initiation and monitoring of immunosuppressive therapies, nutrition interventions, pre-, peri- and postoperative management, as well as structure and function of the multidisciplinary team and integration between primary and secondary care. Twenty research priorities to inform future clinical management are presented, alongside objective measurement of priority importance, determined by 2379 electronic survey responses from individuals living with ulcerative colitis and Crohn's disease, including patients, their families and friends.
- || Humira (adalimumab) / Eisai, AbbVie
I take Humira weekly. My monthly copay is $2500. The assistance program got it to $0. (Twitter) - Dec 1, 2019
- |||| Humira (adalimumab) / Eisai, AbbVie
Clinical, Pricing: How to get to > $20,000,000,000 per year: The #1 drug—Humira—had a price increase from $2,914 to $5,174 over the past 5 years, largely thanks to the 611% jump by the abominable pharmacy benefit managers. Leading to a near doubling of what the patient pays https://t.co/GB60lCuHbd (Twitter) - Nov 30, 2019
- || Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques. (Pubmed Central) - Nov 30, 2019
Summarizing, ELISA, RGA and SPR recognized anti-adalimumab antibodies in few RA patients, showing good agreement among the methodology employed. On the other hand, differences observed between SPR and ELISA or RGA highlight the relevance of the employed technologies in anti-drug antibody identification.
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Adalimumab persistence for inflammatory bowel disease in veteran and insured cohorts. (Pubmed Central) - Nov 29, 2019
Despite being older and having more comorbidities, patients in the VHA, which is an integrated healthcare system, appear to be more likely to remain on ADA at 1 year than patients in the MarketScan database. Further studies of system differences are needed to understand the reasons behind this discrepancy.
- || Humira (adalimumab) / Eisai, AbbVie
Clinical, Retrospective data, Journal, HEOR: Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. (Pubmed Central) - Nov 29, 2019
Further studies of system differences are needed to understand the reasons behind this discrepancy. This retrospective study demonstrates that participation in the PSP augments value-based care by improving outcomes for patients with chronic diseases by helping them not only manage a complex treatment regimen but also lower annual health care costs.
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Diffusion-weighted Imaging Is a Sensitive and Specific Magnetic Resonance Sequence in the Diagnosis of Ankylosing Spondylitis. (Pubmed Central) - Nov 28, 2019
This retrospective study demonstrates that participation in the PSP augments value-based care by improving outcomes for patients with chronic diseases by helping them not only manage a complex treatment regimen but also lower annual health care costs. DWI is informative for diagnosis of AS and nr-axSpA, and has moderate utility in assessment of disease activity or treatment response, with performance similar to that of the SPARCC MRI score.
- || Humira (adalimumab) / Eisai, AbbVie
Biomarker, Clinical, Journal: MiR-146a-5p correlates with clinical efficacy in psoriasis patients treated with the TNF alpha inhibitor Adalimumab. (Pubmed Central) - Nov 28, 2019
Thus, the identification of a blood-based biomarker able to foresee the therapeutic response to treatment is urgently needed, especially considering the high cost of biological therapies. MicroRNAs (miRs) deregulation were previously observed in psoriatic patients, and increasing evidence highlighted that miRs could be novel biomarkers not only with diagnostic/prognostic relevance, but also for monitoring therapeutic response in patients with psoriasis.
- || Clinical, Journal: Efficacy and Survival of Biologic Agents in psoriasis: A practical real-life 12-year experience in a French dermatology department. (Pubmed Central) - Nov 28, 2019
MicroRNAs (miRs) deregulation were previously observed in psoriatic patients, and increasing evidence highlighted that miRs could be novel biomarkers not only with diagnostic/prognostic relevance, but also for monitoring therapeutic response in patients with psoriasis. In a long-term real-life setting, drug survival of ustekinumab is better than that of TNF-a inhibitors for both biologic-naive and biologic-experienced patients with psoriasis.
- || Humira (adalimumab) / Eisai, AbbVie, remtolumab (ABT-122) / AbbVie
Clinical, Journal: Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis. (Pubmed Central) - Nov 28, 2019
P2
Overall, there was no clear evidence that inhibition of the IL-17 pathway provided incremental benefit in the presence of TNF-α inhibition. ClinicalTrials.gov, NCT02433340, NCT02349451.
- || Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, Journal: Paradoxical gastrointestinal reactions in patients taking tumor necrosis factor inhibitors: a rare event that broadens the histologic Spectrum of medication associated injury. (Pubmed Central) - Nov 28, 2019
Our results indicate that among patients with rheumatologic disease, paradoxical reactions of the gastrointestinal tract are associated with TNF inhibitor therapy. Knowledge of this association is important as symptoms and histologic features may improve following medication switch.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Journal: Biologics for hidradenitis suppurativa: an update. (Pubmed Central) - Nov 27, 2019
Adalimumab is the only one internationally registered agent and should be considered first after the conventional therapies appear insufficient. The efficacy and safety profile of some preparations, like infliximab and etanercept was confirmed so far in randomized trials, but there are some new biologics which are still being evaluated and require more rigorous examination.
- || Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Antagonists of TNFα for recurrent miscarriages: 2 Illustrative cases. (Pubmed Central) - Nov 27, 2019
In cases with recurrent obstetrical adverse events and intrauterine deaths, we previously reported the benefit of hydroxychloroquine combination to prednisone. Even few data raised the potential value of TNF antagonists in early recurrent miscarriages, these cases show its potential value in the setting of recurrent refractory chronic intervillositis and unexplained miscarriages.
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part II: Topical, Intralesional, and Systemic medical Management. (Pubmed Central) - Nov 27, 2019
An evidence-based guideline is presented to support health care practitioners as they select optimal medical management strategies is reviewed in this second part of the management guidelines. A therapeutic algorithm informed by the evidence available at the time of the review is provided.
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part I: Diagnosis, Evaluation, and the use of Complementary and Procedural Management. (Pubmed Central) - Nov 27, 2019
Part I of this evidence-based guideline is presented to support health care practitioners as they select optimal management strategies including diagnostic testing, comorbidity screening, and both complementary and procedural treatment options. Recommendations and evidence grading based on the evidence available at the time of the review are provided.
- | Review, Journal: Biologic Therapy in the Treatment of Cutaneous Sarcoidosis: A Literature Review. (Pubmed Central) - Nov 27, 2019
There were also scattered reports of etanercept, rituximab, golimumab, and ustekinumab being utilized as third-line agents with varying degrees of success. Larger and more extensive investigations are required to further assess the adverse effect profile and optimal dosing for managing cutaneous sarcoidosis.
- || Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Pharmacotherapeutic management of psoriasis in adolescents and children. (Pubmed Central) - Nov 27, 2019
Recent evidence suggests that practitioners should consider interceding in the early immunologic psoriatic process to halt this march and stunt immunological scar development. An early investment would provide lasting effects and serious impact in long-term disease modification.
- |||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease @sang_hyoung @EdwardLoftus2 https://t.co/jgfV2YM20y (Twitter) - Nov 27, 2019
- | Journal: Tumour necrosis factor inhibitor exposure and radiographic outcomes in Veterans with rheumatoid arthritis: a longitudinal cohort study. (Pubmed Central) - Nov 27, 2019
One-year changes in radiographic progression were small. Patients with the greatest cumulative TNFi exposure experienced the least progression.